Awardee OrganizationPENNSYLVANIA STATE UNIVERSITY, THE
Description
Abstract Text
Project Summary:
Wolbachia are a genus of endosymbiotic bacteria that comprise a promising, cost-effective tool to curb Zika and
dengue arboviral transmission based on two key facets. First, Wolbachia block pathogenic RNA viruses by
inhibiting their replication in arthropods. Second, Wolbachia selfishly alter sperm and egg via a process termed
cytoplasmic incompatibility (CI) that can drive the bacteria into host populations. CI is expressed as embryonic
lethality in crosses between infected males and uninfected females, but this lethality is rescued in crosses
between infected males and infected females, which are the transmitting sex of Wolbachia. Consequently, CI is
deployed in field trials to either suppress mosquito population sizes or replace uninfected populations with
infected individuals resistant to arboviral infection. We recently exposed a genetic model of CI wherein
expression of two genes (cifA and cifB) causes embryonic lethality when expressed in testes, and expression of
one of the same genes (cifA) rescues lethality when expressed in ovaries. Prior to embryonic lethality, several
post-fertilization defects arise including delayed breakdown of the paternal nuclear envelope, mitotic arrest, and
chromatin bridging. As Wolbachia are stripped from sperm during spermatogenesis, the defects caused by cifA
and cifB may be due to uncharacterized pre-fertilization impairments to sperm integrity. Despite four decades of
intense research and current applications to vector control efforts, the details surrounding these pre-fertilization
impairments remain a central enigma. The overarching hypothesis of the proposed research is cifA and cifB
encode proteins that alter sperm integrity to cause CI. In Aim 1, we will use cytochemical, enzymatic, and
transgenic assays to determine the types, strength, and genetic bases of sperm modifications imposed by the
Cif proteins from wMel Wolbachia released in field trials by the World Mosquito Program. In Aim 2, we will
investigate localization patterns of the Cif proteins during spermatogenesis and storage. We will also identify
important interactions between the Cif proteins and either host or Wolbachia proteins. Knockout and transgenic
experiments will interrogate the necessity of the protein-protein interactions for expression of CI. Finally in Aim
3, we will evaluate if the natural CI proteins or protein complex can be experimentally isolated and successfully
injected into uninfected hosts to recapitulate CI and rescue. In these experiments, we will evaluate a novel
association between the Cif proteins and bacteriophage WO particles from Wolbachia. Studies have yet to yield
a mechanistic breakthrough for the natural CI defects afflicting gametes, and the rising interest in deploying
Wolbachia to curb arbovirus transmission necessitates an urgent understanding of the events underpinning the
CI drive system. If successful, this research will fundamentally advance studies of CI modifications and inform
Wolbachia's ongoing efficacy and delivery as a natural tool to control arthropods worldwide.
Public Health Relevance Statement
Project Narrative:
Mosquitoes infected with the natural bacterium Wolbachia are currently released worldwide to curb the
transmission of Zika and dengue viruses. Wolbachia rapidly spread through host populations by manipulating
sexual reproduction to enhance their own maternal transmission. This research will evaluate the initial
modifications to sexual reproduction that ultimately enable Wolbachia to spread, self-sustain at high
frequencies, and protect local communities from mosquito-borne diseases.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
003403953
UEI
NPM2J7MSCF61
Project Start Date
01-January-2020
Project End Date
31-December-2025
Budget Start Date
01-January-2024
Budget End Date
31-December-2025
Project Funding Information for 2024
Total Funding
$402,500
Direct Costs
$250,000
Indirect Costs
$152,500
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$402,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI143725-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI143725-05
Patents
No Patents information available for 5R01AI143725-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI143725-05
Clinical Studies
No Clinical Studies information available for 5R01AI143725-05
News and More
Related News Releases
No news release information available for 5R01AI143725-05
History
No Historical information available for 5R01AI143725-05
Similar Projects
No Similar Projects information available for 5R01AI143725-05